Jubilant Pharmova Ltd
Jubilant Pharmova Q4 FY24 earnings call: Revenue & Margins
Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹1,759Cr
- +4.8% YoY
- Net profit
- −₹62Cr
- Q4 FY23: −₹100 Cr
- Margin
- 15%
- +2 pp YoY
Guidance rank: #70 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Jubilant Pharmova Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY24 total revenue was Rs. 1,759 Cr, a 5% YoY increase from Rs. 1,678 Cr in Q4 FY23. Q4 FY24 EBITDA: Rs. 289 Cr (16.3% margin), up 20% YoY from Rs. 240 Cr (14.3% margin) in Q4 FY23.
From Jubilant Pharmova Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
2 more points from Jubilant Pharmova Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- CDMO Sterile Injectables: Doubling Spokane capacity for sterile fill and finish (liquid and lyophilization) with a total investment of USD 285 Mn; partly funded by US Govt. cooperative agreement of USD 149.6 Mn.
- Line 3 commercialization expected in FY26; Line 4 expected by FY28. (Page 30)
- Radiopharmacy: Evaluating opportunity for PET radiopharmacy network expansion. (Page 19)
- CDMO Sterile Injectable: Capacity expansion at Spokane on track; Line 3 commercial operations expected by Q1 FY26. (Page 52)
2 more points from Jubilant Pharmova Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jubilant Pharmova Ltd said on order book & pipeline — free account, 30 seconds.
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Jubilant Pharmova Ltd Q4 FY24 results — key figures
| ₹ Cr | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,759 | 1,678 | +4.8% | 1,677 | +4.9% |
| Operating profit (EBITDA) | 271 | 219 | +23.7% | 218 | +24.3% |
| Operating margin | 15% | 13% | +2 pp | 13% | +2 pp |
| Profit before tax | -54 | -86 | — | 101 | -153.5% |
| Net profit (PAT) | -62 | -100 | — | 66 | -193.9% |
| EPS (₹) | -3.68 | -6.15 | — | 4.19 | -187.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmo's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bharat Parenterals (Q4 FY24)
For Q4 FY 2024, consolidated revenue from operations was INR 67.82 crore, up 13.4% YoY (Q4 FY 2023: INR 59.82 crore). Key concall takeaways from Bharat…
- Themis Medicare (Q4 FY24)
97.82 Cr, up 22.11% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Fermenta Biotech (Q4 FY24)
Q4-FY24 Consolidated Operational Revenue: INR 973 Mn, down 7.5% YoY (Page 11) . Key concall takeaways from Fermenta Biotech Ltd's Q4 FY24 earnings call — and…
- Amrutanjan Healt (Q4 FY24)
OTC: ₹108.37 Cr, up 27.57% YoY (Q4 FY23: ₹84.95 Cr) . Key concall takeaways from Amrutanjan Health Care Ltd's Q4 FY24 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q4 FY24 results?
Q4 FY24 total revenue was Rs. 1,759 Cr, a 5% YoY increase from Rs. 1,678 Cr in Q4 FY23. Q4 FY24 EBITDA: Rs. 289 Cr (16.3% margin), up 20% YoY from Rs. 240 Cr (14.3% margin) in Q4 FY23.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
CDMO Sterile Injectables: Doubling Spokane capacity for sterile fill and finish (liquid and lyophilization) with a total investment of USD 285 Mn; partly funded by US Govt.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.